通窍脱敏方治疗变应性鼻炎疗效观察及安全性评价  

Efficacy Observation and Safety Evaluation of Tongqiao Tuomin Prescription(通窍脱敏方)in Treatment of Allergic Rhinitis

作　　者：马凤梅[1] 李丛丛 马雷 邢苗 史飞飞 袁子薇[1] 于向艳[1] MA Fengmei;LI Congcong;MA Lei;XING Miao;SHI Feifei;YUAN Ziwei;YU Xiangyan(Hebei Provincial Hospital of Traditional Chinese Medicine,Shijiazhuang 050011,Hebei,China;Li County Hospital,Li Country 071400,Hebei,China;Ningjin County Integrated Traditional Chinese and Western Medicine Hospital,Ningjin 055550,Hebei,China;Ningjin County Hospital,Ningjin 055550,Hebei,China)

机构地区：[1]河北省中医院,河北石家庄050011 [2]蠡县医院,河北蠡县071400 [3]宁晋县中西医结合医院,河北宁晋055550 [4]宁晋县医院,河北宁晋055550

出　　处：《中华中医药学刊》2024年第6期236-239,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：河北省中医药管理局项目(2023028);河北省中医药类科研计划项目(2018013)。

摘　　要：目的 探讨通窍脱敏方治疗变应性鼻炎的疗效观察及安全性评价。方法 选择2021年7月—2022年7月82例河北省中医院耳鼻喉科诊断为肺气虚寒证型的变应性鼻炎患者作为研究对象,采用随机数字法平均分为观察组与对照组:对照组给予口服氯雷他定片治疗,观察组给予通窍脱敏方治疗。于治疗前、治疗2周及4周后比较两组中医证候积分、临床疗效差异及不良反应发生情况,并随访6个月比较两组患者的复发情况。结果 观察组总有效率明显高于对照组(P<0.05)。随着治疗时间延长,两组患者主症、次症及总积分均逐渐降低(P<0.05);治疗2周及4周后观察组主症、次症及总积分均低于对照组(P<0.05)。随着治疗时间延长,两组患者血清总免疫球蛋白E(Immunoglobulin E,IgE)、嗜酸粒细胞数、白介素17(Interleukin-17,IL-17)均逐渐降低(P<0.05);治疗后2周及4周观察组血清总IgE、嗜酸粒细胞数、IL-17均低于对照组(P<0.05)。两组不良反应发生比较差异无统计学意义(P>0.05)。两组治疗3个月复发率比较差异无统计学意义(P>0.05);治疗后6月观察组复发率低于对照组(P<0.05)。结论 通窍脱敏方治疗变应性鼻炎有更好的临床疗效,更快改善患者鼻炎症状,更好降低机体炎性反应,不仅不良反应少,且大大降低了远期复发,值得临床应用。Objective To observe the curative effect and evaluate the safety of Tongqiao Tuomin Prescription(通窍脱敏方)in the treatment of allergic rhinitis.Methods A total of 82 AR patients who were diagnosed as having lung-Qi deficiency and cold syndrome in Otorhinolaryngology Department of Hebei Provincial Hospital of Traditional Chinese Medicine from July 2021 to July 2022 were selected as the research subjects.They were equally divided into the observation group and the control group by using the random number method.The control group was treated with oral administration of loratadine tablets,and the observation group was given self-made Tongqiao Tuomin Prescription.The TCM syndrome scores,clinical efficacy differences and adverse reac-tions between the two groups were compared before treatment and two or four weeks after treatment.Besides,the recurrence cases of the two groups were compared after a follow-up of six months.Results The total effective rate in the observation group was significantly higher than that in the control group(P<0.05).With the prolongation of treatment time,the main symptoms,sec-ondary symptoms and the total score in the two groups were gradually decreased(P<0.05).The main symptoms,secondary symptoms and total scores in the observation group after two and four weeks of treatment were lower than those in the control group(P<0.05).With the prolongation of treatment time,the serum levels of total immunoglobulin E(IgE),eosinophil count and in-terleukin 17(IL-17)of patients in the two groups were gradually decreased(P<0.05).The serum levels of total IgE,eosino-phil count and IL-17 in the observation group were lower than those in the control group at two and four weeks after treatment(P<0.05).There was no difference in the adverse reactions between the two groups(P>0.05).There was no difference in the recurrence rate within three months between the two groups(P>0.05).The recurrence rate in the observation group was lower than that in the control group six months after treatment(P<0.05).Conclusi

关 键 词：通窍脱敏方 变应性鼻炎 疗效 安全性 复发 

分 类 号：R276.521[医药卫生—中医五官科学]